Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 11, 2015, Pages 2336-2342

  Tersteeg, Claudia ^a   Schiviz, Alexandra ^b   De Meyer, Simon F ^a   Plaimauer, Barbara ^b   Scheiflinger, Friedrich ^b   Rottensteiner, Hanspeter ^b   Vanhoorelbeke, Karen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Baxalta Innovations GmbH   (Austria)

Author keywords

acquired TTP; ADAMTS13; animal model; treatment; VWF

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; POLYCLONAL ANTIBODY; RECOMBINANT ENZYME; RECOMBINANT VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; ADAMTS13 PROTEIN, RAT; ANTIBODY; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; MOLECULAR WEIGHT; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS; VON SILLEBRAND FACTOR RICH THROMBI; ANEMIA, HEMOLYTIC; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; FEASIBILITY STUDY; HUMAN; IMMUNOLOGY; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SEVERITY OF ILLNESS INDEX; SPRAGUE DAWLEY RAT; TIME;

ADAM PROTEINS; ANEMIA, HEMOLYTIC; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84945468921     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306014     Document Type: Article

References (29)

1. Levy GG, Nichols WC, Lian EC, Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 413 488 494. doi: 10.1038/35097008
2. Blombery P, Scully M, Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med 2014 5 15 23. doi: 10.2147/JBM.S46458
3. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B, Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997 89 3097 3103
4. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y, Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002 99 11902 11907. doi: 10.1073/pnas.172277399
5. Furlan M, Robles R, Solenthaler M, Lämmle B, Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998 91 2839 2846
6. Tsai HM, Lian EC, Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 1585 1594. doi: 10.1056/NEJM199811263392203
7. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ, Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007 136 451 461. doi: 10.1111/j.1365-2141.2006.06448.x
8. Cataland SR, Wu HM, Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005 12 359 363. doi: 10.1097/01.moh.0000170534.33517.99
9. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991 325 393 397. doi: 10.1056/NEJM199108083250604
10. Vanhoorelbeke K, De Meyer SF, Animal models for thrombotic thrombocytopenic purpura. J Thromb Haemost 2013 11 suppl 1 2 10. doi: 10.1111/jth.12255
11. Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM, A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood 2012 119 6128 6135. doi: 10.1182/blood-2011-09-380535
12. Plaimauer B, Kremer Hovinga JA, Juno C, Wolfsegger MJ, Skalicky S, Schmidt M, Grillberger L, Hasslacher M, Knöbl P, Ehrlich H, Scheiflinger F, Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011 9 936 944. doi: 10.1111/j.1538-7836.2011.04224.x
13. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, Berg HM, Eikenboom JC, Lenting PJ, Denis CV, Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005 3 2228 2237. doi: 10.1111/j.1538-7836.2005.01571.x
14. Jin SY, Xiao J, Bao J, Zhou S, Wright JF, Zheng XL, AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood 2013 121 3825 3829, S1. doi: 10.1182/blood-2013-02-486779
15. Pickens B, Mao Y, Li D, Siegel DL, Poncz M, Cines DB, Zheng XL, Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 2015 125 3326 3334. doi: 10.1182/blood-2014-07-587139
16. Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C, Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation 2014 129 1320 1331. doi: 10.1161/CIRCULATIONAHA.113.006727
17. Li GW, Rambally S, Kamboj J, Reilly S, Moake JL, Udden MM, Mims MP, Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion 2014 54 1221 1224. doi: 10.1111/trf.12440
18. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, López JA, N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011 121 593 603. doi: 10.1172/JCI41062
19. Feys HB, Roodt J, Vandeputte N, Pareyn I, Mottl H, Hou S, Lamprecht S, Van Rensburg WJ, Deckmyn H, Vanhoorelbeke K, Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood 2012 120 3611 3614. doi: 10.1182/blood-2012-04-421248
20. Callewaert F, Roodt J, Ulrichts H, Stohr T, van Rensburg WJ, Lamprecht S, Rossenu S, Priem S, Willems W, Holz JB, Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 2012 120 3603 3610. doi: 10.1182/blood-2012-04-420943
21. Hoellriegl W, Schiviz A, Hoebarth G, Kubik S, Plaimauer B, Muchitsch EM, Scheiflinger F, Pharmacokinetics of a recombinant ADAMTS13 in mice, rats and macaques. J Thromb Haemost 2013 11 PB3.33-1
22. Derelanko MJ, Hollinger MA, Handbook of Toxicology 1995 Boca Raton, FL CRC Press
23. Plaimauer B, Schiviz A, Kaufmann S, Höllriegl W, Rottensteiner H, Scheiflinger F, Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS13 activity levels in inhibitor-treated rats through defined doses of recombinant ADAMTS13 [published online ahead of print September 4, 2015]. J Thromb Haemost. doi: 10.1111/jth.13137
24. De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carroll MC, Schiviz A, Dietrich B, Rottensteiner H, Scheiflinger F, Wagner DD, Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. Blood 2012 120 5217 5223. doi: 10.1182/blood-2012-06-439935
25. Ferrari S, Palavra K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F, Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica 2014 99 779 787. doi: 10.3324/haematol.2013.094151
26. Feys HB, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, van Rensburg WJ, Anderson PJ, Budde U, Louw VJ, Badenhorst PN, Deckmyn H, Vanhoorelbeke K, Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010 116 2005 2010. doi: 10.1182/blood-2010-04-280479
27. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R, Voorberg J, The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005 93 267 274. doi: 10.1267/THRO05020267
28. Klaus C, Plaimauer B, Studt JD, Dorner F, Lämmle B, Mannucci PM, Scheiflinger F, Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004 103 4514 4519. doi: 10.1182/blood-2003-12-4165
29. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, Bennett CL, Kwaan HC, Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010 95 1555 1562. doi: 10.3324/haematol.2009.019299